ClinVar Miner

Submissions for variant NM_000264.5(PTCH1):c.1420G>A (p.Val474Ile)

gnomAD frequency: 0.00003  dbSNP: rs766898310
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000472706 SCV000549074 likely benign Gorlin syndrome 2024-01-19 criteria provided, single submitter clinical testing
Ambry Genetics RCV002393129 SCV002696619 likely benign Hereditary cancer-predisposing syndrome 2023-06-13 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003317219 SCV004020534 likely benign not specified 2023-06-28 criteria provided, single submitter clinical testing Variant summary: PTCH1 c.1420G>A (p.Val474Ile) results in a conservative amino acid change located in the Sterol-sensing domain (IPR000731) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5e-05 in 359698 control chromosomes (gnomAD and jMorp databases; Tadaka_2021). The observed variant frequency is approximately 3 fold of the estimated maximal expected allele frequency for a pathogenic variant in PTCH1 causing Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome) phenotype (1.7e-05), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.1420G>A in individuals affected with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome) and no experimental evidence demonstrating its impact on protein function have been reported. The following publication was ascertained in the context of this evaluation (PMID: 33179747). Two submitters have reported clinical-significance assessments for this variant to ClinVar after 2014. One submitter classified the variant as likely benign, and one submitter classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely benign.
PreventionGenetics, part of Exact Sciences RCV004551526 SCV004114284 uncertain significance PTCH1-related disorder 2022-09-30 criteria provided, single submitter clinical testing The PTCH1 c.1420G>A variant is predicted to result in the amino acid substitution p.Val474Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.016% of alleles in individuals of East Asian descent in gnomAD ( In the ClinVar database, this variant has been listed as 'uncertain' by one outside laboratory ( At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.